CoChat

A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus

Open access
Quan, Huibiao, Zhang, Huachuan, Wei, Weiping, Fang, Tuanyu, Chen, Daoxiong, Chen, Kaining · 2017 · Experimental and Therapeutic Medicine
Cited by 13

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

The aim of the present study was to explore the effects of various combinations of exenatide, metformin (MET) and biphasic insulin aspart 30 (BIA30) on type 2 diabetes mellitus (T2DM). Two hundred overweight or obese patients newly diagnosed with T2DM were evenly randomized into two groups: A (twice daily for all: Phase I, 5 µg exenatide + 0.5 g MET for 4 weeks, then 10 µg exenatide + 0.5 g MET for 8 weeks; Phase II, 0.5 g MET for 12 weeks; Phase III, 0.3-0.4 U/kg/day BIA30 + 0.5 g MET for 12 weeks) and B (Phases I, II, III matched the phases III, II and I in group A). In groups A and B a significant decrease and increase, respectively, in glycated hemoglobin (HbAlc) and body mass index (BMI) was noted during Phase I. A 3.2±0.4-kg decrease in body weight in group A and a 2.6±0.3-kg increase in group B was observed. In Phase II, HbAlc was significantly increased in both groups (P<0.05). In Phase III, the BMI was increased in group A and reduced in group B (P<0.05). There was a 3.8±0.4-kg weight decrease in group B and 4.2±0.5-kg increase in group A (P<0.05). The combination of exenatide and MET promoted weight loss, glycemic control, β-cell function index, C peptide and adiponectin levels. These results suggested that the combination of exenatide and MET is better than the combination of BIA and MET for the therapy of overweight or obese patients newly diagnosed with T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/etm.2017.4863

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 28

  1. Lewis, 2014, Patients' perspectives of care for type 2 diabetes in Bangladesh-a qualitative study, BMC Public Health, 14, 737, 10.1186/1471-2458-14-737 · DOI
  2. Wang, 2014, Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists, J Diabetes, 6, 164, 10.1111/1753-0407.12077 · doi:10.1111/1753-0407.12077
  3. Umpierrez, 2013, Reshaping diabetes care: The fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice, Endocr Pract, 19, 718, 10.4158/EP12292.RA · DOI
  4. Marchetti, 2009, Autophagy and the pancreatic beta-cell in human type 2 diabetes, Autophagy, 5, 1055, 10.4161/auto.5.7.9511 · DOI · Paper page
  5. Rosenstock, 2012, Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes, Diabetes Care, 35, 955, 10.2337/dc11-1434 · DOI · Paper page
  6. Anderson, 2014, Exenatide extended-release: A once-weekly option for patients with type 2 diabetes, JAAPA, 27, 44, 10.1097/01.JAA.0000443811.42907.a5 · DOI
  7. Carrington, 2014, Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: A retrospective study from a specialist diabetes outpatient clinic, Intern Med J, 44, 345, 10.1111/imj.12377 · DOI
  8. Abdul-Ghani, 2015, Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT): A randomized trial, Diabetes Obes Metab, 17, 268, 10.1111/dom.12417 · DOI · Paper page
  9. Almansari, 2014, Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: Results from the Gulf cohort of the A1 chieve study, Int J Clin Pract, 68, 850, 10.1111/ijcp.12391 · doi:10.1111/ijcp.12391
  10. Bergenstal, 2009, NovoLog Mix-vs.-Exenatide Study Group: Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea, Curr Med Res Opin, 25, 65, 10.1185/03007990802597951 · DOI · Paper page
  11. Yang, 2009, Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents, Chin Med J (Engl), 122, 1704
  12. Davidson, 2009, Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: A meta-analysis, Clin Ther, 31, 1641, 10.1016/j.clinthera.2009.08.011 · DOI
  13. 2009, American Diabetes Association: Standards of medical care in diabetes-2009, Diabetes Care, 32, S13, 10.2337/dc09-S013 · DOI · Paper page
  14. Kim, 2010, Triple combination therapy using metformin, thiazolidinedione and a GLP-1 analog or DPP-IV inhibitor in patients with type 2 diabetes mellitus, Korean Diabetes J, 34, 331, 10.4093/kdj.2010.34.6.331 · DOI
  15. Kann, 2006, Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride, Exp Clin Endocrinol Diabetes, 114, 527, 10.1055/s-2006-949655 · DOI · Paper page
  16. 2014, General Assembly of the World Medical Association: World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects, J Am Coll Dent, 81, 14
  17. Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 · DOI · Paper page
  18. Steppan, 2001, The hormone resistin links obesity to diabetes, Nature, 409, 307, 10.1038/35053000 · DOI · Paper page
  19. Yamamoto, 2013, Association between reduction of plasma adiponectin levels and risk of bacterial infection after gastric cancer surgery, PloS One, 8, e56129, 10.1371/journal.pone.0056129 · DOI
  20. Shehzad, 2012, Adiponectin: Regulation of its production and its role in human diseases, Hormones (Athens), 11, 8, 10.1007/BF03401534 · DOI · Paper page
  21. Freeman, 2002, West of Scotland Coronary Prevention Study: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland coronary prevention study, Diabetes, 51, 1596, 10.2337/diabetes.51.5.1596 · DOI · Paper page
  22. Xu, 2002, Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity, Diabetes, 51, 1876, 10.2337/diabetes.51.6.1876 · DOI · Paper page
  23. Frias, 2016, Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): A 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4: 1004–1016, 2016, Lancet Diabetes Endocrinol, 4, 1004, 10.1016/S2213-8587(16)30267-4 · DOI · Paper page
  24. Mohammadzadeh, 2011, Hypoadiponectinemia in obese subjects with type II diabetes: A close association with central obesity indices, J Res Med Sci, 16, 713
  25. Vimaleswaran, 2008, A novel association of a polymorphism in the first intron of adiponectin gene with type 2 diabetes, obesity and hypoadiponectinemia in Asian Indians, Human Genet, 123, 599, 10.1007/s00439-008-0506-8 · DOI
  26. Weyer, 2001, Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia, J Clin Endocrinol Metab, 86, 1930, 10.1210/jcem.86.5.7463 · DOI · Paper page
  27. Weise, 2009, Exenatide-associated ischemic renal failure, Diabetes Care, 32, e22, 10.2337/dc08-1309 · DOI · Paper page
  28. Barnett, 2007, Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 29: 2333–2348, 2007, Clin Ther, 29, 2333, 10.1016/j.clinthera.2007.11.006 · DOI · Paper page

Cited by

See all 13

Metadata

Authors
Quan, H., Zhang, H., Wei, W., Fang, T., Chen, D., & Chen, K.
Venue
Experimental and Therapeutic Medicine
Published
2017-08-02
Volume
14
Issue
4
Pages
3279-3287
ISSN
  • 1792-0981 (ISSN-L)
  • 1792-1015
OpenAlex
W2740178513
Cited by
13
References
7
FWCI
0.19
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.3892/etm.2017.4863
The paper
Quan, H., Zhang, H., Wei, W., Fang, T., Chen, D., & Chen, K. (2017). A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus. Experimental and Therapeutic Medicine. https://doi.org/10.3892/etm.2017.4863

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.